These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 2851948

  • 1. [Biological monitoring of treatment with low molecular weight heparin].
    Aiach M, Sié P.
    Ann Biol Clin (Paris); 1988; 46(9):715-8. PubMed ID: 2851948
    [Abstract] [Full Text] [Related]

  • 2. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.
    Kitchen S, Iampietro R, Woolley AM, Preston FE.
    Thromb Haemost; 1999 Oct; 82(4):1289-93. PubMed ID: 10544915
    [Abstract] [Full Text] [Related]

  • 3. Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti-Xa assays: interlaboratory variability and requirement for an agreed low molecular weight heparin standard.
    Sié P, Aillaud MF, de Prost D, Droullé C, Forestier F, Guedj P, Juhan-Vague I, Polack B, Potron G, Roncato M.
    Thromb Haemost; 1987 Oct 28; 58(3):879-83. PubMed ID: 2829376
    [Abstract] [Full Text] [Related]

  • 4. [Monitoring of plasma concentration of low molecular weight heparin--comparative evaluation with chromogenic and clotting assays].
    Katagiri H, Itoh S, Uchida T, Kawai Y, Watanabe K.
    Rinsho Byori; 1999 Nov 28; 47(11):1046-51. PubMed ID: 10590682
    [Abstract] [Full Text] [Related]

  • 5. In vitro anticoagulation monitoring of low-molecular-weight heparin.
    Wang JQ, Shi XB, Yang JG, Hu DY.
    Chin Med J (Engl); 2009 May 20; 122(10):1199-202. PubMed ID: 19493471
    [Abstract] [Full Text] [Related]

  • 6. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J.
    J Mal Vasc; 1987 May 20; 12 Suppl B():68-70. PubMed ID: 2834495
    [Abstract] [Full Text] [Related]

  • 7. Monitoring low molecular weight heparins.
    Garon JE.
    Clin Leadersh Manag Rev; 2003 May 20; 17(1):47-50. PubMed ID: 12592880
    [Abstract] [Full Text] [Related]

  • 8. Limitations of the chronometric assays to determine plasma antifactor Xa activity during low molecular weight heparin therapy.
    Boneu B, Faruel-Bille V, Pierrejean D, Gabaig AM.
    Nouv Rev Fr Hematol (1978); 1991 May 20; 33(4):287-91. PubMed ID: 1664095
    [Abstract] [Full Text] [Related]

  • 9. A new chronometric assay to determine plasma antifactor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins.
    Dignac M, Gabaig AM, Cambus JP, Boneu B.
    Nouv Rev Fr Hematol (1978); 1994 May 20; 35(6):545-9. PubMed ID: 8152901
    [Abstract] [Full Text] [Related]

  • 10. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective.
    Favaloro EJ, Bonar R, Aboud M, Low J, Sioufi J, Wheeler M, Lloyd J, Street A, Marsden K, RCPA QAP in Haematology.
    Lab Hematol; 2005 May 20; 11(3):157-62. PubMed ID: 16174600
    [Abstract] [Full Text] [Related]

  • 11. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P, Kuitunen A, Petäjä J, Ilveskero S, Lassila R.
    Thromb Haemost; 2008 Feb 20; 99(2):427-34. PubMed ID: 18278195
    [Abstract] [Full Text] [Related]

  • 12. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J, Haaf B, Dempfle CE, Stehle G, Heene DL.
    Nephrol Dial Transplant; 1995 Feb 20; 10(2):217-22. PubMed ID: 7753456
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood.
    Konstantinidis K, Gerasimidis T, Verdy E, Elalamy I, Samama MM, Gerotziafas GT.
    Thromb Haemost; 2007 Jan 20; 97(1):109-18. PubMed ID: 17200777
    [Abstract] [Full Text] [Related]

  • 14. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
    Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennett M, Horton S, Shann F, Lane G, Ross-Smith M, Monagle P.
    Thromb Res; 2007 Jan 20; 120(3):347-51. PubMed ID: 17118432
    [Abstract] [Full Text] [Related]

  • 15. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G, Brand P, Meyer T, Herpich C, Müllinger B, Brom J, Weidinger G, Kohlhäufl M, Häussinger K, Spannagl M, Schramm W, Siekmeier R.
    J Physiol Pharmacol; 2007 Nov 20; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [Abstract] [Full Text] [Related]

  • 16. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
    Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M.
    Am J Clin Pathol; 2008 Sep 20; 130(3):446-54. PubMed ID: 18701419
    [Abstract] [Full Text] [Related]

  • 17. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA, Spinler SA, Wittkowsky A, Dager WE.
    Ann Pharmacother; 2009 Jun 20; 43(6):1064-83. PubMed ID: 19458109
    [Abstract] [Full Text] [Related]

  • 18. Heparin and low-molecular-weight heparin.
    Gray E, Mulloy B, Barrowcliffe TW.
    Thromb Haemost; 2008 May 20; 99(5):807-18. PubMed ID: 18449410
    [Abstract] [Full Text] [Related]

  • 19. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V, Béguin S, Boneu B, Hemker HC.
    Thromb Haemost; 1997 Feb 20; 77(2):312-6. PubMed ID: 9157588
    [Abstract] [Full Text] [Related]

  • 20. [Current status of low molecular weight heparin].
    Maillet P.
    Phlebologie; 1992 Feb 20; 45(2):179-83. PubMed ID: 1326773
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.